Valbenazine

Vesicular Monoamine Transporter 2 Inhibitor — NERVOUS SYSTEM

Key facts

Valbenazine is an ofp drug in the Vesicular Monoamine Transporter 2 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Vesicular Monoamine Transporter 2 Inhibitors. DrugCentral lists 3 molecular targets, including SLC18A2, Slc18a2 and KCNH2. Recorded indications include Tardive dyskinesia.

• Approval status: ofp (first approved 2017 by the FDA).
• Drug class: Vesicular Monoamine Transporter 2 Inhibitor.
• Mechanism of action: Vesicular Monoamine Transporter 2 Inhibitors.
• Molecular targets: SLC18A2, Slc18a2 and KCNH2 (3 listed in DrugCentral).
• Indications: Tardive dyskinesia.
• ATC code: N07XX13 (Other nervous system drugs).
• Molecular formula: C24H38N2O4; molecular weight 418.58 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Tardive dyskinesia

Mechanism & targets

• Mechanism of action (MoA): Vesicular Monoamine Transporter 2 Inhibitors
• Established pharmacologic class: Vesicular Monoamine Transporter 2 Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
Synaptic vesicular amine transporter	SLC18A2	inhibitor	Ki 8.52
Synaptic vesicular amine transporter	Slc18a2	inhibitor	Ki 6.73
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 5.77

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2022-03-28	PMDA	—	Mitsubishi Tanabe Pharma Corporation
2017-04-11	FDA	—	NEUROCRINE BIOSCIENCES INC

ATC classification

ATC code	Therapeutic hierarchy
N07XX13	NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CYP2D6 · Actionable PGx
• HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drooling	1859.7
Parkinsonism	1678.8
Somnolence	1385.0
Tremor	1056.5
Dyskinesia	710.3
Sedation	644.7
Hospitalisation	503.8
Akathisia	433.4
Death	416.1
Therapeutic product effect decreased	410.8
Drug ineffective	378.0
Adverse drug reaction	345.2

Chemical structure

• Molecular formula: C₂₄H₃₈N₂O₄
• Molecular weight: 418.58 g/mol
• CAS number: 1025504-45-3
• InChIKey: GEJDGVNQKABXKG-CFKGEZKQSA-N
• PubChem CID: 14580381

COC1=CC2=C(C=C1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Valbenazine used for?

DrugCentral lists the following indications for Valbenazine: Tardive dyskinesia.

How does Valbenazine work?

Valbenazine is classified as Vesicular Monoamine Transporter 2 Inhibitors; its molecular targets in DrugCentral include SLC18A2 (inhibitor), Slc18a2 (inhibitor) and KCNH2.

When was Valbenazine first approved?

Valbenazine was first approved by the FDA in 2017.

What drug class does Valbenazine belong to?

Valbenazine is in the Vesicular Monoamine Transporter 2 Inhibitor class.

What is the chemical formula of Valbenazine?

Valbenazine has the molecular formula C24H38N2O4 and a molecular weight of 418.58 g/mol.

Sources

• DrugCentral drug card 5227 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2364639 — compound record and bioactivity
• PubChem CID 14580381 — chemical identifiers
• DrugBank DB11915 — drug record
• FDA UNII 54K37P50KH — substance identity
• DailyMed: FDA labels for Valbenazine — current prescribing information (label search)
• UniProt Q05940 (SLC18A2) — target protein
• UniProt Q12809 (KCNH2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.